Tag: Clascoterone
-
Clascoterone 5% Achieves Promising Phase 3 Hair Growth Outcomes
Cosmo Pharmaceuticals has reported encouraging topline findings from 2 large, identically designed phase 3 trials evaluating clascoterone 5% topical solution for male androgenetic alopecia (AGA). If ultimately approved, the drug could represent the first new therapeutic mechanism for AGA in over 30 years—a notable development for a condition with high prevalence and limited treatment options.1…